

# Mastocytosis

[View the current Mastocytosis InDepth page on BioPortfolio.com](#) (PDF)

(<http://www.bioportfolio.com/indepth/Mastocytosis.html>) - Regularly Updated.

Mastocytosis is a group of rare disorders of both children and adults caused by the presence of too many mast cells and CD34+ mast cell precursors in a person's body. ([From the Wikipedia article Mastocytosis.](#))



## Recent Publications on Mastocytosis:

- [Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.](#)  
*We describe a case of systemic mastocytosis associated with...* 17th November, 2009  
Division of Hematology, Department of Internal Medicine, National Hospital- Intern Med. 2009;48(22):1973-8. Epub 2009 Nov 16.
- [Anaphylaxis: Recent advances in assessment and treatment.](#)  
*The incidence rate of anaphylaxis is increasing, particularly during the...* 17th November, 2009  
Department of Pediatrics, Faculty of Medicine, University of Manitoba,- J Allergy Clin Immunol. 2009 Oct;124(4):625-36; quiz 637-8. ([DOI Direct Link](#))
- [On being metachromatic: Mystique and misunderstanding in mastocytosis.](#)  
*We describe a case of systemic mastocytosis associated with...* 10th November, 2009  
Department of Medicine, Division of Hematology, Stanford University School- Am J Hematol. 2009 Oct 23. ([DOI Direct Link](#))
- [Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis. Subcellular Distribution and Role of the Transforming Oncoprotein KIT D816V.](#)  
*Recent data suggest that the signal transducer and activator of...* 7th November, 2009  
From the Department of Internal Medicine I,\* Division of Hematology &- Am J Pathol. 2009 Nov 5. ([DOI Direct Link](#))
- [Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.](#)  
*Cytoreductive therapy in systemic mastocytosis (SM) includes several drugs...* 6th November, 2009  
Divisions of Hematology, Mayo Clinic, Rochester, Minnesota.- Am J Hematol. 2009 Oct 9. ([DOI Direct Link](#))
- [Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.](#)  
*Cytoreductive therapy in systemic mastocytosis (SM) includes several drugs...* 6th November, 2009  
- Allergy. 2009 Nov 4. ([DOI Direct Link](#))
- [Mast cell leukemia with rapidly progressing portal hypertension.](#)  
*Reported herein is an autopsy case of mast cell leukemia, a rare form of...* 4th November, 2009  
Department of Molecular Pathology and Tumor Pathology, Akita University- Pathol Int. 2009

- Nov;59(11):817-22. ([DOI Direct Link](#))
- [Pediatric Mastocytosis Is a Clonal Disease Associated with D\(816\)V and Other Activating c-KIT Mutations.](#)  
*Adult mastocytosis is an incurable clonal disease associated with c-KIT...*30th October, 2009  
 [1] Service de Dermatologie, Hopital Necker, Paris, France [2] CEREMAST,- J Invest Dermatol. 2009 Oct 29. ([DOI Direct Link](#))
  - [Midostaurin \(PKC412\) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.](#)  
*BACKGROUND: KIT tyrosine kinase inhibitors (TKI), such as nilotinib or...*29th October, 2009  
 Department of Internal Medicine I, Division of Hematology and- Clin Exp Allergy. 2009 Nov;39(11):1711-20. ([DOI Direct Link](#))
  - [Identification of pro-apoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.](#)  
*Systemic mastocytosis (SM) is a myeloid neoplasm involving mast cells (MC)...*24th October, 2009  
 Department of Internal Medicine I, Division of Hematology and- Blood. 2009 Oct 22. ([DOI Direct Link](#))
  - [What, if anything, is specific about having a rare disorder? Patients' judgements on being ill and being rare.](#)  
*BACKGROUND: Growing efforts are made to improve the situation of persons...*21st October, 2009  
 Groupe de Sociologie Politique et Morale, Ecole des Hautes Etudes en- Health Expect. 2009 Dec;12(4):361-70. Epub 2009 Oct 14. ([DOI Direct Link](#))
  - [Are we ready to downregulate mast cells?](#)  
*Downregulation of mast cells (MCs) function and/or survival is warranted...*20th October, 2009  
 Department of Pharmacology and Experimental Therapeutics, School of- Curr Opin Immunol. 2009 Oct 16. ([DOI Direct Link](#))
  - [The recent article on 'Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy' by Niedoszytko et al.](#)  
*Downregulation of mast cells (MCs) function and/or survival is warranted...*15th October, 2009  
 - Allergy. 2009 Nov;64(11):1685. ([DOI Direct Link](#))
  - [Expulsion of secondary Trichinella spiralis infection in rats occurs independently of mucosal mast cell release of mast cell protease II.](#)  
*Our aim was to elucidate the contribution of mucosal mast cells to the...*9th October, 2009  
 James A. Baker Institute for Animal Health, Cornell University, Ithaca, NY- J Immunol. 2009 Nov 1;183(9):5816-22. Epub 2009 Oct 7. ([DOI Direct Link](#))
  - [Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.](#)  
*The 2008 WHO classification system for hematological malignancies is...*7th October, 2009  
 Division of Hematology, Department of Medicine, Mayo Clinic, 200 First- Nat Rev Clin Oncol. 2009 Nov;6(11):627-37. Epub 2009 Oct 6. ([DOI Direct Link](#))

## BioNews Results for Mastocytosis

- [Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations](#)  
*Journal of Investigative Dermatology: Oct 29 2009 10:51AM Matching: mastocytosis*



## Mastocytosis Patents:

- 7557106- [Substituted pyrimidines useful as protein kinase inhibitors](#)
- 7582629- [Derivatives of isothiazol-3\(2H\)-one 1,1-dioxides as liver X receptor modulators](#)
- 7582644- [Pyrimidyl sulphone amide derivatives as chemokine receptor modulators](#)
- 7582648- [Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds](#)
- 7582654- [Heterocyclic inhibitors of potassium channel function](#)
- 7582672- [Compounds for the treatment of CRTH2-mediated diseases and conditions](#)
- 7585500- [Fully human monoclonal antibodies to IL-13](#)
- 7585867- [Substituted thiazolo\[4,5-d\]pyrimidin-2\(3H\)-one](#)
- 7585883- [Substituted pyridines and their uses](#)
- 7589124- [Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use](#)
- 7589200- [5-Fluoro-4N-phenyl-4-pyrimidineamine compounds](#)
- 7579473- [c-Met modulators and methods of use](#)
- 7579342- [Pteridine compounds for the treatment of psoriasis](#)
- 7576132- [Arginine silicate inositol complex and use thereof](#)
- 7557127- [HDAC inhibitor](#)
- 7557191- [Sialoadhesin factor-2 antibodies](#)
- 7557207- [Spiro 2,4-pyrimidinediamine compounds and their uses](#)
- 7557210- [2,4-pyrimidinediamine compounds and their uses](#)
- 7560466- [Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds](#)
- 7563585- [Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein \(TXNL\)](#)
- 7563787- [Substituted pyrazole compounds](#)
- 7563892- [Prodrugs of 2,4 pyrimidinediamine compounds and their uses](#)
- 7563894- [Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors](#)
- 7569667- [Isolated soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof](#)
- 7592349- [Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors](#)
- 7592358- [Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds](#)
- 7605176- [.beta.-ketoamide compounds with MCH antagonistic activity](#)
- 7610096- [Methods for treating central nervous system damage](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7612092- [Nitrogen-containing aromatic derivatives](#)
- 7612098- [Amorphous hydrous esomeprazole magnesium](#)
- 7612208- [Crystalline form of the salt of 4-\(3-chloro-4-\(cyclopropylaminocarbonyl\)aminophenoxy\)-7-methoxy-6-quinolin-2-carboxamide or the solvate of the salt and a process for preparing the same](#)
- 7615555- [Piperidine derivatives as modulators of chemokine receptor CCR5](#)

- 7615610- [Modified trafficking patterns for arrestin and G-protein-coupled receptors via arrestin-ubiquitin chimera](#)
- 7615611- [Human cytokine receptor](#)
- 7618965- [\(Arylamidoanilino\)nitroethylene compounds](#)
- 7605171- [\(3,4-disubstituted\)propanoic carboxylates as S1P \(Edg\) receptor agonists](#)
- 7604951- [Method for identifying compounds that modulate RXR associated processes with IgE production](#)
- 7604797- [Compositions and methods for treating burns](#)
- 7592373- [Amide compounds with MCH antagonistic activity and medicaments comprising these compounds](#)
- 7592429- [Sclerostin-binding antibody](#)
- 7595154- [Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha \(PDGFRA\) mutation](#)
- 7598050- [Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein](#)
- 7598245- [Aminotriazole compounds useful as inhibitors of protein kinases](#)
- 7601712- [Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient](#)
- 7601713- [Kinase inhibitors and their uses](#)
- 7601749- [Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof](#)
- 7601843- [4-\(2-furoyl\)aminopiperidine compound useful as therapeutic agent for itching](#)
- 7601868- [Amine derivative](#)
- 7618977- [Method of treating dermatitis comprising administering a chymase inhibitor](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

